drugset / Trial / NCT03437330

Empagliflozin Effect on Glucose Toxicity

NCT03437330

Phase 4 Withdrawn University Hospital Tuebingen
RandomizedParallel-groupOpen-labelTreatment

Summary

Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study

Timeline

Start
2021-10-27
Primary completion
2023-05-03
Completion
2023-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg Oral
Comparator insulin glargine Protein / enzyme biologic